Ultragenyx Pharmaceutical Inc (RARE) released Loss for second quarter of -$114.9 million
The company's bottom line came in at -$114.9 million, or -$1.17 per share. This compares with -$131.6 million, or -$1.52 per share, last year.
The company's revenue for the period rose 13.3% to $166.5 million from $147.0 million last year.
Ultragenyx Pharmaceutical Inc earnings at a glance (GAAP) :
-Earnings: -$114.9 Mln. vs. -$131.6 Mln. last year.-EPS: -$1.17 vs. -$1.52 last year.-Revenue: $166.5 Mln vs. $147.0 Mln last year.
-Guidance:Full year revenue guidance: $640 - $670 mln
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.